Clinical Trial Update: A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study to determine the dose and regimen of Durvalumab as monotherapy or in combination with Pomalidomide with or without Dexamethasone in relapsed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Durvalumab (Imfinzi) (durvalumab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED